USFDA issues warning letter to Intas Pharma for Sanand plant

The USFDA inspected the manufacturing facility from November 22 to December 2, 2022. A warning letter is issued when the US health regulator finds that a manufacturer has significantly violated its regulations

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/osf1lAr
via gqrds

Comments

Popular posts from this blog

SC transfers PIL seeking implementation of law on mental health care to NHRC

Hospital-insurer conflict: Will latest circular by NMC help in reducing the pain of health insurance policyholders?

Over 9.19 crore hospital admissions facilitated under Ayushman Bharat since 2018